CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma

PURPOSE: Tumor mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs) have been well recognized as molecular determinants of immunotherapy responsiveness. In this study, we aimed to construct a TMB prognostic model and explore biomarkers that have predictive potential for prognosis and ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhou, Feng, Yanqi, Li, Piao, Wang, Shennan, Liu, Xinyue, Xia, Shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000921/
https://www.ncbi.nlm.nih.gov/pubmed/35418778
http://dx.doi.org/10.2147/IJGM.S352851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000921/
https://www.ncbi.nlm.nih.gov/pubmed/35418778
http://dx.doi.org/10.2147/IJGM.S352851

Ejemplares similares